Position paper: Ipecac syrup.
Syrup of ipecac should not be administered routinely in the management of poisoned patients. In experimental studies the amount of marker removed by ipecac was highly variable and diminished with time. There is no evidence from clinical studies that ipecac improves the outcome of poisoned patients and its routine administration in the emergency department should be abandoned. There are insufficient data to support or exclude ipecac administration soon after poison ingestion. Ipecac may delay the administration or reduce the effectiveness of activated charcoal, oral antidotes, and whole bowel irrigation. Ipecac should not be administered to a patient who has a decreased level or impending loss of consciousness or who has ingested a corrosive substance or hydrocarbon with high aspiration potential. A review of the literature since the preparation of the 1997 Ipecac Syrup Position Statement revealed no new evidence that would require a revision of the conclusions of that Statement.
D000818:Animals; D000931:Antidotes / Q000008:administration & dosage / Q000009:adverse effects; D000075202:Contraindications; D004639:Emetics / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007486:Ipecac / Q000008:administration & dosage / Q000009:adverse effects; D011041:Poisoning / Q000150:complications / Q000188:drug therapy
D000931:Antidotes; D004639:Emetics; D007486:Ipecac